Symbols / AGEN Stock $3.44 +5.52% Agenus Inc.

Healthcare • Biotechnology • United States • NCM
AGEN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Jennifer S. Buell Ph.D.
Exch · Country NCM · United States
Market Cap 142.89M
Enterprise Value 142.57M
Income 64.39M
Sales 123.87M
FCF (ttm) -50.64M
Book/sh -7.68
Cash/sh 0.84
Employees 81
Insider 10d —
IPO Feb 08, 2000
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E inf
Forward P/E -1.50
PEG 1.44
P/S 1.15
P/B -0.45
P/C —
EV/EBITDA 9.39
EV/Sales 1.15
Quick Ratio 0.36
Current Ratio 0.38
Debt/Eq —
LT Debt/Eq —
EPS (ttm) 0.00
EPS next Y -2.30
EPS Growth —
Revenue Growth 40.20%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-10
Earnings (prior) 2026-05-11
ROA 2.53%
ROE —
ROIC —
Gross Margin 96.90%
Oper. Margin 44.62%
Profit Margin 52.16%
Shs Outstand 41.54M
Shs Float 38.63M
Insider Own 6.69%
Instit Own 25.92%
Short Float 10.70%
Short Ratio 3.97
Short Interest 4.39M
52W High 7.34
vs 52W High -53.13%
52W Low 2.71
vs 52W Low 26.94%
Beta —
Impl. Vol. 25.00%
Rel Volume 1.01
Avg Volume 790.39K
Volume 795.68K
Target (mean) $15.50
Tgt Median $15.50
Tgt Low $8.00
Tgt High $23.00
# Analysts 2
Recom Strong_buy
Prev Close $3.26
Price $3.44
Change 5.52%
About

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$15.50
Mean price target
2. Current target
$3.44
Latest analyst target
3. DCF / Fair value
$-21.94
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.44
Low
$8.00
High
$23.00
Mean
$15.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-09-10 reit HC Wainwright & Co. Buy → Buy $23
2025-08-28 reit HC Wainwright & Co. Buy → Buy $23
2025-06-04 main Baird Neutral → Neutral $6
2025-06-04 up HC Wainwright & Co. Neutral → Buy $25
2025-05-13 reit HC Wainwright & Co. Neutral → Neutral —
2025-05-13 main Baird Neutral → Neutral $4
2025-04-30 reit HC Wainwright & Co. Neutral → Neutral —
2025-03-18 reit HC Wainwright & Co. Neutral → Neutral —
2025-03-12 main Baird Neutral → Neutral $3
2025-03-12 reit HC Wainwright & Co. Neutral → Neutral —
2025-01-22 reit HC Wainwright & Co. Neutral → Neutral —
2024-12-05 reit HC Wainwright & Co. Neutral → Neutral —
2024-11-29 reit HC Wainwright & Co. Neutral → Neutral $7
2024-11-12 main HC Wainwright & Co. Neutral → Neutral $7
2024-08-14 main B. Riley Securities Buy → Buy $18
2024-07-19 down Jefferies Buy → Hold $7
2024-07-18 down HC Wainwright & Co. Buy → Neutral $9
2024-06-28 reit HC Wainwright & Co. Buy → Buy $40
2024-05-24 reit HC Wainwright & Co. Buy → Buy $40
2024-05-07 reit HC Wainwright & Co. Buy → Buy $40
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-01 ARMEN GARO H. Chief Executive Officer — 4,233 $3.84 $16,255
2026-04-17 ARMEN GARO H. Chief Executive Officer — 3,403 $4.79 $16,300
2026-04-02 ARMEN GARO H. Chief Executive Officer — 4,629 $3.33 $15,415
2026-04-01 HARRISON THOMAS L Director — 9,228 $3.32 $30,628
2026-03-20 ARMEN GARO H. Chief Executive Officer — 3,983 $3.71 $14,777
2026-03-06 ARMEN GARO H. Chief Executive Officer — 4,994 $2.96 $14,782
2026-02-20 ARMEN GARO H. Chief Executive Officer — 4,829 $3.06 $14,777
2026-02-06 ARMEN GARO H. Chief Executive Officer — 5,027 $2.94 $14,779
2026-01-23 ARMEN GARO H. Chief Executive Officer — 4,562 $3.24 $14,781
2026-01-09 ARMEN GARO H. Chief Executive Officer — 3,780 $3.91 $14,780
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
114.20
+10.37%
103.46
-33.81%
156.31
+59.47%
98.02
Operating Revenue
5.61
+125.67%
2.48
-94.05%
41.74
-20.85%
52.74
Cost Of Revenue
80.36
-48.49%
156.01
-34.36%
237.68
+20.49%
197.26
Reconciled Cost Of Revenue
80.36
-48.49%
156.01
-34.36%
237.68
+20.49%
197.26
Gross Profit
33.84
+164.39%
-52.55
+35.41%
-81.37
+18.01%
-99.23
Operating Expense
54.39
-24.33%
71.88
-8.71%
78.74
-2.80%
81.01
Selling General And Administration
54.39
-24.33%
71.88
-8.71%
78.74
-2.80%
81.01
General And Administrative Expense
54.39
-24.33%
71.88
-8.71%
78.74
-2.80%
81.01
Other Gand A
54.39
-24.33%
71.88
-8.71%
78.74
-2.80%
81.01
Total Expenses
134.75
-40.87%
227.89
-27.98%
316.42
+13.71%
278.27
Operating Income
-20.56
+83.48%
-124.43
+22.28%
-160.10
+11.17%
-180.24
Total Operating Income As Reported
-20.17
+83.26%
-120.47
+24.49%
-159.55
+11.08%
-179.43
EBITDA
62.19
+161.39%
-101.30
+30.58%
-145.92
+9.84%
-161.85
Normalized EBITDA
-39.12
+62.83%
-105.26
+28.14%
-146.48
+8.86%
-160.72
Reconciled Depreciation
10.00
-25.06%
13.34
-1.80%
13.59
+95.62%
6.95
EBIT
52.19
+145.52%
-114.64
+28.13%
-159.51
+5.50%
-168.79
Total Unusual Items
101.31
+2462.24%
3.95
+611.15%
0.56
+149.55%
-1.12
Total Unusual Items Excluding Goodwill
101.31
+2462.24%
3.95
+611.15%
0.56
+149.55%
-1.12
Special Income Charges
101.31
+2462.24%
3.95
+611.15%
0.56
+149.55%
-1.12
Other Special Charges
—
—
—
1.94
Restructuring And Mergern Acquisition
-0.39
+90.21%
-3.95
-611.15%
-0.56
+31.78%
-0.81
Net Income
0.12
+100.05%
-227.21
+7.55%
-245.76
-11.67%
-220.07
Pretax Income
-3.08
+98.67%
-232.27
+9.78%
-257.44
-11.61%
-230.66
Net Non Operating Interest Income Expense
-55.27
+53.01%
-117.63
-20.12%
-97.92
-58.29%
-61.86
Interest Expense Non Operating
55.27
-53.01%
117.63
+20.12%
97.92
+58.29%
61.86
Net Interest Income
-55.27
+53.01%
-117.63
-20.12%
-97.92
-58.29%
-61.86
Interest Expense
55.27
-53.01%
117.63
+20.12%
97.92
+58.29%
61.86
Other Income Expense
72.75
+643.52%
9.78
+1549.92%
0.59
-94.82%
11.45
Other Non Operating Income Expenses
-2.22
-138.08%
5.83
+15656.76%
0.04
-99.71%
12.57
Gain On Sale Of Business
100.92
0.00
0.00
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-3.08
+98.67%
-232.27
+9.78%
-257.44
-11.61%
-230.66
Net Income From Continuing Operation Net Minority Interest
0.12
+100.05%
-227.21
+7.55%
-245.76
-11.67%
-220.07
Net Income From Continuing And Discontinued Operation
0.12
+100.05%
-227.21
+7.55%
-245.76
-11.67%
-220.07
Net Income Continuous Operations
-3.08
+98.67%
-232.27
+9.78%
-257.44
-11.61%
-230.66
Minority Interests
3.20
-36.79%
5.06
-56.67%
11.68
+10.34%
10.58
Normalized Income
-101.20
+56.22%
-231.17
+6.15%
-246.32
-12.50%
-218.95
Net Income Common Stockholders
-0.10
+99.96%
-227.43
+7.54%
-245.97
-11.66%
-220.29
Diluted EPS
—
-10.59
+22.98%
-13.75
+12.08%
-15.64
Basic EPS
—
-10.59
+22.98%
-13.75
+12.08%
-15.64
Basic Average Shares
—
21.47
+20.00%
17.89
+27.02%
14.09
Diluted Average Shares
—
21.47
+20.00%
17.89
+27.02%
14.09
Diluted NI Availto Com Stockholders
-0.10
+99.96%
-227.43
+7.54%
-245.97
-11.66%
-220.29
Earnings From Equity Interest
-26.34
0.00
0.00
—
Preferred Stock Dividends
0.22
+0.47%
0.21
+0.94%
0.21
+0.47%
0.21
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
226.80
+0.23%
226.27
-27.92%
313.91
-24.09%
413.56
Current Assets
133.44
+192.79%
45.57
-59.46%
112.42
-47.25%
213.12
Cash Cash Equivalents And Short Term Investments
3.00
-92.59%
40.44
-46.87%
76.11
-60.64%
193.36
Cash And Cash Equivalents
3.00
-92.59%
40.44
-46.87%
76.11
-57.40%
178.67
Other Short Term Investments
—
—
0.00
-100.00%
14.68
Receivables
7.01
+1622.36%
0.41
-98.42%
25.84
+842.58%
2.74
Accounts Receivable
1.83
+349.88%
0.41
-98.42%
25.84
+842.58%
2.74
Prepaid Assets
0.79
-66.09%
2.31
-71.41%
8.10
-41.44%
13.83
Assets Held For Sale Current
121.55
0.00
—
—
Other Current Assets
1.09
-54.91%
2.42
+1.81%
2.37
-25.74%
3.19
Total Non Current Assets
93.36
-48.33%
180.70
-10.32%
201.50
+0.53%
200.43
Net PPE
23.21
-84.25%
147.40
-9.59%
163.03
-0.77%
164.29
Gross PPE
70.68
-67.86%
219.95
-2.23%
224.97
+3.03%
218.36
Accumulated Depreciation
-47.47
+34.57%
-72.55
-17.13%
-61.94
-14.55%
-54.08
Properties
0.00
0.00
0.00
0.00
Land And Improvements
10.06
-18.15%
12.29
+0.00%
12.29
+0.00%
12.29
Buildings And Improvements
0.00
-100.00%
5.84
+0.00%
5.84
+3.24%
5.65
Machinery Furniture Equipment
29.22
-62.95%
78.87
-1.51%
80.08
+8.32%
73.93
Construction In Progress
0.06
-92.86%
0.78
-48.15%
1.51
-97.73%
66.46
Other Properties
7.74
-71.64%
27.31
-7.76%
29.61
-5.32%
31.27
Leases
23.61
-75.12%
94.86
-0.82%
95.64
+232.59%
28.76
Goodwill And Other Intangible Assets
27.13
-1.23%
27.47
-5.72%
29.13
-8.08%
31.70
Goodwill
24.09
+0.00%
24.09
-2.55%
24.72
-2.92%
25.47
Other Intangible Assets
3.04
-10.04%
3.38
-23.46%
4.41
-29.17%
6.23
Investments And Advances
24.28
0.00
—
—
Long Term Equity Investment
24.28
0.00
—
—
Non Current Accounts Receivable
15.44
—
—
—
Other Non Current Assets
3.31
-43.32%
5.83
-37.51%
9.34
+109.66%
4.45
Total Liabilities Net Minority Interest
504.66
-5.26%
532.70
+15.23%
462.30
-1.32%
468.46
Current Liabilities
323.49
+46.11%
221.40
-13.48%
255.90
+35.43%
188.95
Payables And Accrued Expenses
108.10
+20.55%
89.67
-11.63%
101.48
+39.63%
72.68
Payables
82.99
+35.00%
61.47
+0.04%
61.45
+50.09%
40.94
Accounts Payable
82.99
+35.00%
61.47
+0.04%
61.45
+50.09%
40.94
Current Accrued Expenses
25.12
-10.94%
28.20
-29.55%
40.03
+26.13%
31.74
Current Debt And Capital Lease Obligation
45.79
+365.07%
9.85
-25.35%
13.19
+423.83%
2.52
Current Debt
44.66
+1555.11%
2.70
+1747.95%
0.15
-74.61%
0.57
Other Current Borrowings
10.46
+309.76%
2.55
—
0.43
Current Capital Lease Obligation
1.14
-84.11%
7.15
-45.20%
13.04
+571.33%
1.94
Current Deferred Liabilities
0.00
-100.00%
0.03
+72.22%
0.02
-99.85%
12.27
Current Deferred Revenue
0.00
-100.00%
0.03
+72.22%
0.02
-99.85%
12.27
Other Current Liabilities
169.59
+39.18%
121.85
-13.71%
141.21
+39.14%
101.49
Total Non Current Liabilities Net Minority Interest
181.17
-41.80%
311.29
+50.82%
206.40
-26.16%
279.51
Long Term Debt And Capital Lease Obligation
10.11
-88.11%
85.02
+12.95%
75.28
-0.83%
75.91
Long Term Debt
—
30.47
+138.67%
12.77
+1.46%
12.58
Long Term Capital Lease Obligation
10.11
-81.47%
54.55
-12.73%
62.51
-1.29%
63.33
Non Current Deferred Liabilities
1.14
+0.00%
1.14
+0.00%
1.14
+0.00%
1.14
Non Current Deferred Revenue
1.14
+0.00%
1.14
+0.00%
1.14
+0.00%
1.14
Other Non Current Liabilities
169.92
-24.52%
225.13
+73.21%
129.98
-35.80%
202.45
Preferred Securities Outside Stock Equity
—
—
—
—
Stockholders Equity
-271.11
+16.93%
-326.38
-103.57%
-160.33
-161.65%
-61.28
Common Stock Equity
-271.11
+16.93%
-326.38
-103.57%
-160.33
-161.65%
-61.28
Capital Stock
0.35
+49.58%
0.24
+19.80%
0.20
-93.55%
3.06
Common Stock
0.35
+49.58%
0.24
+19.80%
0.20
-93.55%
3.06
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
35.32
+49.44%
23.63
+19.86%
19.72
+29.06%
15.28
Ordinary Shares Number
35.32
+49.44%
23.63
+19.86%
19.72
+29.06%
15.28
Additional Paid In Capital
1,911.74
+2.91%
1,857.66
+3.43%
1,796.10
+9.21%
1,644.66
Retained Earnings
-2,182.76
+0.01%
-2,182.88
-11.62%
-1,955.67
-14.37%
-1,709.91
Gains Losses Not Affecting Retained Earnings
-0.44
+68.60%
-1.40
-46.39%
-0.95
-204.37%
0.92
Treasury Stock
—
—
0.00
0.00
Minority Interest
-6.75
-133.82%
19.96
+67.01%
11.95
+87.41%
6.38
Other Equity Adjustments
-0.44
+68.60%
-1.40
-46.39%
-0.95
-204.37%
0.92
Total Equity Gross Minority Interest
-277.86
+9.32%
-306.42
-106.51%
-148.38
-170.27%
-54.90
Total Capitalization
-271.11
+8.38%
-295.91
-100.53%
-147.56
-203.04%
-48.69
Working Capital
-190.05
-8.09%
-175.83
-22.54%
-143.48
-693.63%
24.17
Invested Capital
-226.46
+22.77%
-293.21
-98.90%
-147.42
-206.36%
-48.12
Total Debt
55.90
-41.08%
94.87
+7.24%
88.47
+12.80%
78.43
Net Debt
41.66
—
—
—
Capital Lease Obligations
11.24
-81.78%
61.70
-18.34%
75.56
+15.76%
65.27
Net Tangible Assets
-298.24
+15.72%
-353.85
-86.76%
-189.47
-103.78%
-92.97
Tangible Book Value
-298.24
+15.72%
-353.85
-86.76%
-189.47
-103.78%
-92.97
Current Notes Payable
34.20
+23323.29%
0.15
+0.00%
0.15
+0.00%
0.15
Duefrom Related Parties Non Current
15.44
0.00
—
—
Investmentsin Associatesat Cost
24.28
0.00
—
—
Notes Receivable
5.18
0.00
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-77.19
+51.24%
-158.31
+29.39%
-224.20
-27.84%
-175.37
Cash Flow From Continuing Operating Activities
-77.19
+51.24%
-158.31
+29.39%
-224.20
-27.84%
-175.37
Net Income From Continuing Operations
-3.08
+98.67%
-232.27
+9.78%
-257.44
-11.61%
-230.66
Depreciation Amortization Depletion
10.00
-25.06%
13.34
-1.80%
13.59
+95.62%
6.95
Depreciation And Amortization
10.00
-25.06%
13.34
-1.80%
13.59
+95.62%
6.95
Other Non Cash Items
-51.19
-537.82%
11.69
+182.69%
-14.14
-172.12%
19.61
Stock Based Compensation
13.77
-20.82%
17.39
-23.96%
22.87
+24.72%
18.34
Asset Impairment Charge
0.23
-88.14%
1.97
0.00
-100.00%
6.11
Operating Gains Losses
-100.37
-2087.27%
-4.59
-133.66%
-1.96
+90.08%
-19.80
Gain Loss On Investment Securities
-0.39
+90.21%
-3.95
-611.15%
-0.56
+31.78%
-0.81
Unrealized Gain Loss On Investment Securities
26.12
+1593.84%
1.54
-27.47%
2.13
—
Change In Working Capital
27.33
-16.16%
32.60
+203.12%
10.76
-55.34%
24.08
Change In Receivables
-1.73
-106.82%
25.34
+208.03%
-23.46
-19330.33%
0.12
Changes In Account Receivables
-1.73
-106.82%
25.34
+208.03%
-23.46
-19330.33%
0.12
Change In Inventory
—
—
—
—
Change In Prepaid Assets
1.26
-78.21%
5.78
-4.14%
6.03
-49.16%
11.87
Change In Payables And Accrued Expense
28.00
+1202.89%
2.15
-94.88%
41.98
+392.25%
8.53
Change In Accrued Expense
4.50
+3208.09%
0.14
-99.34%
20.61
+913.42%
2.03
Change In Payable
23.50
+1067.41%
2.01
-90.58%
21.37
+229.01%
6.49
Change In Account Payable
23.50
+1067.41%
2.01
-90.58%
21.37
+229.01%
6.49
Change In Other Working Capital
-0.20
+70.64%
-0.67
+95.14%
-13.79
-486.49%
3.57
Investing Cash Flow
1.19
+4322.22%
0.03
-99.21%
3.40
+110.12%
-33.61
Cash Flow From Continuing Investing Activities
1.19
+4322.22%
0.03
-99.21%
3.40
+110.12%
-33.61
Net PPE Purchase And Sale
0.35
+163.95%
-0.55
+91.62%
-6.59
+78.78%
-31.06
Purchase Of PPE
-0.01
+98.96%
-0.58
+94.21%
-9.95
+81.24%
-53.06
Sale Of PPE
0.36
+1395.83%
0.02
-99.29%
3.36
-84.71%
22.00
Capital Expenditure
-0.01
+98.96%
-0.58
+94.21%
-9.95
+81.24%
-53.06
Net Investment Purchase And Sale
0.84
+45.25%
0.58
-94.20%
9.99
+2592.99%
0.37
Purchase Of Investment
0.00
0.00
+100.00%
-20.04
+18.62%
-24.63
Sale Of Investment
0.84
+45.25%
0.58
-98.07%
30.03
+20.14%
25.00
Net Business Purchase And Sale
—
0.00
0.00
+100.00%
-2.92
Purchase Of Business
—
0.00
0.00
+100.00%
-2.92
Gain Loss On Sale Of Business
-100.92
0.00
0.00
—
Financing Cash Flow
36.59
-70.21%
122.84
+2.48%
119.87
+25.08%
95.83
Cash Flow From Continuing Financing Activities
36.59
-70.21%
122.84
+2.48%
119.87
+25.08%
95.83
Net Issuance Payments Of Debt
2.35
-75.32%
9.52
+206.64%
-8.93
-1721.63%
-0.49
Issuance Of Debt
12.50
-37.50%
20.00
0.00
0.00
Repayment Of Debt
-10.15
+3.15%
-10.48
-17.42%
-8.93
-1721.63%
-0.49
Long Term Debt Issuance
12.50
-37.50%
20.00
0.00
0.00
Long Term Debt Payments
-10.15
+3.15%
-10.48
-17.42%
-8.93
-1721.63%
-0.49
Net Long Term Debt Issuance
2.35
-75.32%
9.52
+206.64%
-8.93
-1721.63%
-0.49
Net Common Stock Issuance
36.05
-7.15%
38.82
-69.67%
127.98
+34.13%
95.42
Common Stock Payments
-0.09
0.00
+100.00%
-5.17
-36.50%
-3.79
Repurchase Of Capital Stock
-0.09
0.00
+100.00%
-5.17
-36.50%
-3.79
Proceeds From Stock Option Exercised
0.17
-73.88%
0.65
-19.83%
0.81
-10.13%
0.90
Net Other Financing Charges
-1.97
-102.67%
73.85
+12286.63%
-0.61
—
Changes In Cash
-39.41
-11.17%
-35.45
+64.88%
-100.94
+10.80%
-113.15
Effect Of Exchange Rate Changes
0.05
+118.08%
-0.26
+58.60%
-0.63
-503.85%
-0.10
Beginning Cash Position
44.07
-44.76%
79.78
-56.01%
181.34
-38.44%
294.60
End Cash Position
4.71
-89.31%
44.07
-44.76%
79.78
-56.01%
181.34
Free Cash Flow
-77.20
+51.41%
-158.89
+32.14%
-234.16
-2.50%
-228.44
Interest Paid Supplemental Data
1.18
-48.42%
2.28
-28.09%
3.17
+177.17%
1.14
Common Stock Issuance
36.14
-6.92%
38.82
-70.84%
133.16
+34.22%
99.21
Issuance Of Capital Stock
36.14
-6.92%
38.82
-70.84%
133.16
+34.22%
99.21
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category